Skip to content
stoqly

Science Applications Intl

SAIC Nasdaq Diversified Support Services Financials FY2017–FY2026

Science Applications Intl's revenue fell 2.9% to $7.3 billion in fiscal 2026. Its operating margin was 7.2%, down from 7.5% a year earlier. Free cash flow was $577 million, up 26.0%. It paid out $515 million in dividends and buybacks, 89% of free cash flow. The diluted share count fell 7.9%.

Last close · Oct 23, 2026

$145.73

1.5%
Value it Compare
Revenue Total sales reported in the income statement.
$7.3B
2.9% vs prior year
Operating margin Operating income as a share of revenue.
7.2%
0.4 pts
Net income Profit after all expenses, interest and tax.
$358M
1.1%
Free cash flow Cash from operations minus capital spending.
$577M
26.0%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
12.8%
0.1 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$6.2B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
17.0x
On $8.56 EPS (TTM)

What Science Applications Intl does

No business description yet.

Legal name
Science Applications International Corporation
Fiscal year ends
January 30, 2026
Latest annual report
—
Accession · CIK
0001571123-26-000029
0001571123

Revenue and margins

Science Applications Intl had $7.3B of revenue in fiscal 2026, down 2.9% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

From fiscal 2017 to 2026, diluted EPS grew 10.6% a year. Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $577M in fiscal 2026, 8.0% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Science Applications Intl returned $515M to shareholders in fiscal 2026, 89% of free cash flow. The diluted share count fell 7.9%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Science Applications Intl yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of −$2.3B and divides by 46.5M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today 17.0x · peers 22.4x · sector 26.0x.

Balance sheet

Cash, debt and the ratios that show how comfortably Science Applications Intl can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments $106M$109M$94.0M$56.0M$182M
Debt incl. finance leases $2.5B$2.4B$2.1B$2.2B$2.5B
Net debt / EBITDA 4.8x4.3x2.6x3.7x4.2x
Debt / equity 1.6x1.4x1.2x1.4x1.7x
Interest coverage 4.4x4.2x5.9x4.7x5.2x
Current ratio 0.9x1.1x1.0x0.8x1.2x
Quick ratio 0.9x1.0x1.0x0.8x1.2x
Total assets $5.7B$5.5B$5.3B$5.2B$5.4B
Total liabilities $4.1B$3.8B$3.5B$3.7B$3.9B
Shareholders' equity $1.6B$1.7B$1.8B$1.6B$1.5B
Net debt (− = net cash) $2.4B$2.3B$2.0B$2.2B$2.3B

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.5M

6 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

DateInsiderTradeSharesPriceValueFiling
Sep 22, 2026 Cush C. DavidDirector Bought 1,000 $132.50 $0.1M Form 4
Apr 9, 2026 Srinivas AttiliEVP, Civilian Bought 100 $94.96 $0.0M Form 4
Dec 31, 2025 Srinivas AttiliEVP, Civilian Bought 100 $101.26 $0.0M Form 4
Dec 23, 2025 Vincent P. DiFronzoEVP,-Air Force & Comb Commands Bought 150 $102.89 $0.0M Form 4
Dec 16, 2025 Hilary HagemanEVP General Counsel, Secretary Bought 100 $100.21 $0.0M Form 4
Dec 16, 2025 James ReaganInterim CEO, Director Bought 1,000 $100.17 $0.1M Form 4
Dec 16, 2025 Prabu NatarajanEVP, Chief Financial Officer Bought 2,000 $100.49 $0.2M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY24FY25FY26
Net income is positive ✓ ✓ ✓
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✓ ✕ ✓
Cash from operations exceeds net income ✕ ✓ ✓
Debt fell relative to assets ✓ ✕ ✕
Current ratio rose ✕ ✕ ✓
Share count didn't rise ✓ ✓ ✓
Gross margin rose ✓ ✓ ✓
Revenue rose relative to assets ✓ ✓ ✕
F-score 7 / 96 / 97 / 9
Accruals ratio 1.5%−2.5%−4.7%
Altman Z'' 2.311.842.21

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Science Applications Intl SAIC $6.2B −2.9% 7.2% 8.0% 12.8% 17.0x 7
KBR KBR $5.0B 1.0% 10.0% 6.6% 15.8% 11.8x 7 Compare →
CACI International CACI $14.1B 10.9% 9.6% 8.2% 8.8% 26.0x 5 Compare →
Cintas CTAS $90.6B 8.9% 23.1% 16.7% 31.7% 44.2x 8 Compare →
Copart CPRT $27.8B 0.4% 35.4% 27.2% 19.6% 18.7x 4 Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue $4.4B $4.5B $4.7B $6.4B $7.1B $7.4B $7.7B $7.4B $7.5B $7.3B
Gross profit $439M $411M $464M $706M $792M $859M $888M $872M $892M $872M
Research and development $4.0M $4.0M $5.0M $7.0M $6.0M $4.0M $1.0M $4.0M $12.0M $13.0M
Operating income $263M $256M $220M $370M $390M $462M $501M $741M $563M $521M
Interest expense $52.0M $44.0M $53.0M $90.0M $122M $105M $120M $125M $121M $101M
Pretax income $212M $214M $170M $286M $271M $358M $375M $620M $428M $387M
Income tax $69.0M $35.0M $33.0M $57.0M $60.0M $79.0M $72.0M $143M $66.0M $29.0M
Net income $143M $179M $137M $226M $209M $277M $300M $477M $362M $358M
Diluted EPS $3.12 $4.02 $3.11 $3.83 $3.56 $4.77 $5.38 $8.88 $7.17 $7.70
Diluted shares 0.05B 0.04B 0.04B 0.06B 0.06B 0.06B 0.06B 0.05B 0.05B 0.05B
Cash flow
Cash from operations $273M $217M $184M $458M $755M $518M $532M $396M $494M $609M
Capital expenditure $15.0M $22.0M $28.0M $21.0M $46.0M $36.0M $25.0M $27.0M $36.0M $32.0M
Free cash flow $258M $195M $156M $437M $709M $482M $507M $369M $458M $577M
Depreciation and amortization $23.0M $23.0M $23.0M $36.0M $32.0M $37.0M $32.0M $26.0M $25.0M $30.0M
Stock-based compensation $31.0M $27.0M $45.0M $37.0M $42.0M $46.0M $48.0M $68.0M $53.0M $64.0M
Acquisitions $0.0M $0.0M $1.0B $0.0M $1.2B $255M $0.0M $0.0M $0.0M $203M
Share buybacks $180M $186M $69.0M $197M $34.0M $226M $267M $382M $558M $445M
Dividends paid $54.0M $54.0M $53.0M $87.0M $87.0M $86.0M $83.0M $79.0M $75.0M $70.0M
Dividends and buybacks $234M $240M $122M $284M $121M $312M $350M $461M $633M $515M
Balance sheet
Cash and short-term investments $210M $144M $237M $188M $171M $106M $109M $94.0M $56.0M $182M
Total debt $1.0B $1.0B $2.1B $1.9B $2.5B $2.5B $2.4B $2.1B $2.2B $2.5B
Finance lease liabilities $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Current assets $901M $950M $1.4B $1.4B $1.3B $1.3B $1.2B $1.1B $1.2B $1.2B
Current liabilities $623M $695M $897M $1.1B $1.3B $1.4B $1.1B $1.2B $1.4B $982M
Inventory $71.0M $68.0M $74.0M $84.0M $78.0M $64.0M $71.0M $3.0M $0.0M $0.0M
Property and equipment, net $60.0M $61.0M $103M $91.0M $108M $100M $92.0M $91.0M $104M $110M
Total assets $2.0B $2.1B $4.6B $4.7B $5.7B $5.7B $5.5B $5.3B $5.2B $5.4B
Total liabilities $1.7B $1.7B $3.1B $3.3B $4.2B $4.1B $3.8B $3.5B $3.7B $3.9B
Shareholders' equity $349M $327M $1.5B $1.4B $1.5B $1.6B $1.7B $1.8B $1.6B $1.5B
Margins
Gross margin 9.9% 9.2% 10.0% 11.1% 11.2% 11.6% 11.5% 11.7% 11.9% 12.0%
Operating margin 5.9% 5.8% 4.7% 5.8% 5.5% 6.3% 6.5% 10.0% 7.5% 7.2%
EBITDA margin 6.4% 6.3% 5.2% 6.4% 6.0% 6.8% 6.9% 10.3% 7.9% 7.6%
Net margin 3.2% 4.0% 2.9% 3.5% 3.0% 3.8% 3.9% 6.4% 4.8% 4.9%
FCF margin 5.8% 4.4% 3.4% 6.9% 10.1% 6.5% 6.6% 5.0% 6.1% 8.0%
Returns
Return on capital 14.5% 17.9% 7.8% 9.1% 8.6% 9.1% 10.1% 14.7% 12.7% 12.8%
Return on capital employed 18.4% 18.3% 8.7% 10.2% 9.7% 10.5% 11.4% 17.3% 14.1% 12.7%
Return on equity 39.2% 53.0% 15.1% 15.6% 14.1% 17.5% 18.1% 27.4% 21.5% 23.3%
Return on assets 6.9% 8.7% 4.1% 4.9% 4.0% 4.8% 5.3% 8.8% 6.9% 6.8%
Growth
Revenue growth 2.9% 0.3% 4.6% 36.9% 10.6% 4.8% 4.2% −3.4% 0.5% −2.9%
Net income growth 22.2% 25.2% −23.5% 65.0% −7.5% 32.5% 8.3% 59.0% −24.1% −1.1%
EPS growth 26.3% 28.9% −22.6% 23.2% −7.1% 34.0% 12.8% 65.1% −19.3% 7.4%
FCF growth 25.2% −24.4% −20.0% 180.1% 62.2% −32.0% 5.2% −27.2% 24.1% 26.0%
Share count change −3.2% −3.1% −0.9% 33.8% −0.5% −1.0% −4.0% −3.8% −6.0% −7.9%
Financial health
Net debt / EBITDA 2.9x 3.2x 7.6x 4.3x 5.6x 4.8x 4.3x 2.6x 3.7x 4.2x
Debt / equity 3.0x 3.1x 1.4x 1.4x 1.6x 1.6x 1.4x 1.2x 1.4x 1.7x
Interest coverage 5.1x 5.8x 4.2x 4.1x 3.2x 4.4x 4.2x 5.9x 4.7x 5.2x
Current ratio 1.5x 1.4x 1.6x 1.3x 1.0x 0.9x 1.1x 1.0x 0.8x 1.2x
Quick ratio 1.3x 1.3x 1.5x 1.2x 1.0x 0.9x 1.0x 1.0x 0.8x 1.2x
Capital allocation
Capex / revenue 0.3% 0.5% 0.6% 0.3% 0.7% 0.5% 0.3% 0.4% 0.5% 0.4%
Stock comp / revenue 0.7% 0.6% 1.0% 0.6% 0.6% 0.6% 0.6% 0.9% 0.7% 0.9%
Payouts / FCF 90.7% 123.1% 78.2% 65.0% 17.1% 64.7% 69.0% 124.9% 138.2% 89.3%
Quality scores
Piotroski F-score 7.0 7.0 7.0 5.0 6.0 7.0 8.0 7.0 6.0 7.0
Altman Z'' 2.4 2.3 1.9 1.8 1.2 1.3 1.8 2.3 1.8 2.2
Accruals ratio −6.2% −1.9% −1.4% −5.0% −10.5% −4.2% −4.1% 1.5% −2.5% −4.7%

Source: SEC EDGAR XBRL filings (CIK 0001571123). Data updated October 18, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open